Thank afternoon, you, Thank joining for you call. our us And good Leiv. today update for everyone. business
to ITK for continue on our the to immunotherapy. a significant cancer opportunity focus soquelitinib We approach novel inhibitor as potential develop selective
of in our increased interest confidence enrollment I/Ib and that solid comprehensive preclinical very on immunologic Lymphoma a bioRXiv publication the trial a in in and chemical function of hematologic second, at models international meeting; article of mechanism properties, of major tumors; action in soquelitinib lymphoma soquelitinib Over key Phase months, last and we presenting that several the our including: from achieved T-cell and additional advancements trial peripheral broader in data further ongoing few
peripheral T-cell in an several study third a discuss the the monotherapy Lymphoma submission to with our on solid in within remain Phase initiate we our relapsed to next And for months. the III by trial Phase package PTCL. year FDA and track registration and plan to strategy III end data the tumor upcoming or of third, trial start soquelitinib meeting quarter of for our proposed
inhibitor. the consortium the Recent Phase nivolumab. this Ib/II the trial end receptor frontline new exciting accumulating cancer the program combination Ib this Phase In of completion are of of of is include addition, data by we highlights anticipated with kidney the adenosine from conducted Initial advancement Phase the in with from trial XA data by II ipilimumab study or portion renal portion into with in and cell therapy cancer the of year. ciforadenant
Second, myeloid presentation mechanism Japan joint interactions. of AACR of T-cell at effects ciforadenant its Cancer meeting action the Association on the and on
with Now and I the of progress will on our ciforadenant. soquelitinib share details more with
for feel foundation in very we following towards continue We medicine progressing immunotherapy strengthen T-cell cancer a soquelitinib importantly lymphoma. special trial potential and the because for of a scientific registration are soquelitinib to and the III is the use attributes. randomized Briefly, clinical potential Phase of
ITK attractive we T-cell one, through modulation antitumor system along effects. on an inhibit in monotherapy target, off-target molecular with its has shown have ability no early of the Three, safety chronic significant the demonstrated the effects with precisely-defined patients, to the profile enzyme kinase known durable differentiation. other responses Two, specific multipronged dosing. clinical with a in clinic, very Number data very sick with activity immune
is represents complement Phase development. We option and immunotherapy range the checkpoint inhibitors has with approach broad synergize to remain selective distinct or of view that We a discuss novel opportunity also and with checkpoint most It the advanced this and FDA to blockade. ITK believe as a patients initial proposed our a to We inhibitor with is an in opportunity study. immune important with be across soquelitinib is treatment potential the meet from new and for quarter relapsed first it platform cancer soquelitinib as on in class cancers potential III to diseases. track PTCL an to
comparing would interim progression-free monotherapy include agents. planned primary patients trial that of The total randomized be study survival. endpoint anticipate to a soquelitinib also XXX study is chemotherapy analysis. will standard-of-care approximately the The We an
anticipate successful, end to begun III Assuming We Phase and the the up investigators. trial our meeting centers before FDA potential sites and we internationally. plan recruitment year, initiate we be to will trial with of XX the have of
preeminent premier field. the lymphoma that enlisted private have in leaders we far, So academic are centers and
is and investigator the in field studies lymphoma. in extensively a conducted principle III leader Phase has published in T-cell Our
Conference the were malignant relapsed a June. of soquelitinib dose, with of International The for reported Phase interim at in evaluable in including presented trial total times XX clinical XXXX, was in enrolled as patients on most the the recent lymphoma T-cell XX, day May a that patients XXX-milligram data lymphoma at response. I/Ib on We patients XX optimum X
six with milliliter per evaluable blood, of The absolute responses ALC, or with To showing control disease were studies lymphocyte of briefly T-cells the markers. XX seen cytotoxic patients. infiltration objective of tumors these of with in and XX tumor cytolytic findings of of an XX complete and of action, for T-cell three XX partial there exhaustion on responses and with out patients, the with increased mechanism responses, demonstrating of patients partial of continued increased three count, confirmed tumor. recap, were regression blood reduction that responses tissue showed one cubic above in laboratory XXX Correlative capacity patients,
by clinical continue the in We patients results lab enroll the are to and study. and encouraged
interest We present an abstract for trial the Annual additional Further generated submitted has plan where been this have to ASH inhibition preclinical of soquelitinib through highlighted trial. novel tumors of by of the on hematologic a to mechanism on response December, our Meeting and recent information and antitumor selective in immune data in ITK the solid which action. to enhance publication we bioRXiv,
and it cells that inhibitor Two, reduces tumors. publication immune selectively while including covalent, of of other are infiltration reverses the cytotoxic more takeaways inhibits T-cell to ITK in soquelitinib, binds prolonged kinase that closely-related resting a response. to one, these sparing it RLK. and Key is leads And kinases, into lymphocyte irreversible potent a function from activation killer three, resulting increasing exhaustion, cells, and or
immune-based T-cell is a to T-cell exhaustion of immune major and unanticipated were well therapy CAR a The effects major T-cell cause of on often limitation checkpoint exhaustion as address therapies. as therapies. current resistance
the T-cell production the that ThX-skewing necrosis soquelitinib leading gamma ThX factor, rejection. important of also tumor are of to ThX cytokines production We and in inhibited tumor cytokines, found and in interferon which function
soquelitinib cell models, colon, several showed vivo in mouse T-cell melanoma, tumors. led in activity to publication B and antitumor tumor including renal, The
anticipate we complement activity have will well therapies with as soquelitinib inhibitors. monotherapy synergize other multipronged its checkpoint as Given immune such as effects, or
studies initiate or first our indication soquelitinib are enhance the mechanism cell solid we agent the to tumors. and described in and results and the to single publication, by A studies will checkpoint of to ability responses therapy. evaluate bioRXiv renal developed, excited immune following to frontline planning first clinical been inhibitor We're in protocol be in patients second now has relapse cancer
to antitumor evaluate primary this activity. study The will of be objective
Cancer starting strong we and planning are have other with The interest principle, this of solid as well. will has reasons soquelitinib to and Research for lead several renal trial. proof Consortium establish cancer tumors We for expressed in Kidney cell
and soquelitinib a role cytokines. platform for inhibitor the Finally, develop their autoimmune function ThXX we based secreted and that crucial many use to ITK ThX on play cytokines findings diseases our diseases. continue potential inflammatory in inhibits in These
So, in fibrosis soon. approach preclinical publish auto-immunoallergic new such on represents autoimmune activity dermatitis, of many this immune of soquelitinib a asthma, diseases plan and to treatment atopic diseases. the in allergic data as We idea other the diseases
our trial Ib/II in partner-led and ipilimumab with programs, trial the to ciforadenant, of is for renal first-line potential successfully adenosine Consortium being cancer II the evaluating currently AXA currently trial inhibitor enrolling Turning Ib of safety patients in in a patients the has The therapy portion receptor with no combination dosing. our a change Kidney completed, as metastatic Phase and in enrolled clinical been portion Phase the Cancer cell Phase nivolumab. are Research
before of time XXXX. is XX The lines, current to based expected on up enroll clinical data end initial patients. the to we anticipate trial interim And
antagonist. is agent other with that may publication our antibody the best to You AXA study was XXXX recall or anti-CTLA-X ciforadenant this combine that on showing based the
data the Cancer preclinical of presentation combination between blockade and checkpoint The the myeloid data cells Association ciforadenant In highlighted June, to blockade that several data of promoted International cells that for involvement a the the presented synergy pro-inflammatory Research for Medicine helper production the demonstrated team of of supporting at production Association Cancer leads leading response. pro-inflammatory American with ciforadenant immune Precision to immune and our checkpoint Cancer ThX ciforadenant Conference. new cytokines. and Japanese The
This of genes. in on gene This trials found for signature human a is adenosine expression biomarker that the based confirms expression a our biomarker published called response. the earlier clinical work myeloid eight measuring gene signature as myeloid
and data updates preclinical by We clinical forward this the our look the of year. are end to by on trial encouraged sharing
enroll Phase I/Ib For in and and squamous non-small with and China alone neck cell mupadolimab, is Pharmaceuticals a cancers. cell patients partner, in in trial cancer pembrolizumab mupadolimab together with continuing head Angel our lung to clinical patients with
of range progress approach new opportunity to inhibition a cancers of strategic immunotherapy immune remain on focused lymphomas the as look to a executing beyond significant in broad extend ITK made We initiatives on and second solid the XXXX. quarter our We to and diseases. advancing
We III to FDA enrollment Phase metastatic trial a the milestones have I a programs, upcoming soquelitinib with our of data monotherapy cell include this for clinical of key trial trial, discuss ciforadenant interim cancer. Phase tumor registration soquelitinib, quarter Phase I/Ib which number and of our the in continued of solid from renal study II initiation the Phase in frontline meeting
provide cancer programs Our to us significant diseases. needs and address in patient opportunities immune multiple
the significant on So in In to coming to and multiple optionality updates forward our our shots providing shareholders. for build we quarters. on efficiently closing, value goal give look us programs the potential
Operator? turn the call for Q&A. operator now to will the I over
